Close Menu

Pharmaceutical companies' interest in RNA interference is waning, says The New York Times' Andrew Pollack. Roche, Pfizer, and Abbott have all ceased to work on RNAi, though Roche's Klaus Stein says that he has "no doubt that at a certain point in time RNAi will make it to the market," but that there were "opportunities that have higher priorities" to focus on. Pollack adds that it is fairly common for a new technique to enjoy a moment of vogue before some interest in it is lost.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.